0.18
-0.0135(-6.97%)
Currency In USD
Address
201 East Fifth Street
Cincinnati, OH 45202
United States of America
Phone
513 620 4101
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
February 18, 2022
| Name | Title | Pay | Year Born |
| Mr. Joseph Hernandez M.S., MBA | Chief Executive Officer, Pres & Executive Chairman | 1.01M | 1973 |
| Dr. Neil J. Campbell MA, MBA | President, Chief Executive Officer & Director | 0 | 1960 |
| Mr. James R. Sapirstein M.B.A., R.Ph. | Interim Executive Chairman | 65,625 | 1961 |
| Dr. Brian Price Ph.D. | Head of Technology Strategy | 126,479 | N/A |
| Ms. Erin Henderson | Chief Business Officer & Corporate Secretary | 526,905 | 1975 |
| Mr. Jon M. Garfield | Chief Financial Officer & Interim Principal Executive Officer | 543,750 | 1964 |
| Dr. Ali I. Fattom Ph.D. | Head of Science & Discovery | 0 | N/A |
| Dr. Ronald R. Cobb Ph.D. | Head of Science & Discovery | 0 | N/A |
| Mr. Andrew D. Skibo Ph.D. | Global Head of Biologics Operations | 0 | N/A |
| Mr. Bruce Harmon | Chief Financial Officer | 0 | 1958 |
| Mr. Theodore Scott Yoho | Head of Business Development | 0 | N/A |
| Mr. Frank A. Jaeger M.A., M.B.A. | Senior Vice President of Marketing & Business Development | 0 | 1971 |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer | 0 | N/A |
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
